Boussard & Gavaudan Investment Management LLP Takes Position in Solventum Co. (NYSE:SOLV)

Boussard & Gavaudan Investment Management LLP bought a new position in Solventum Co. (NYSE:SOLV) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 63,638 shares of the company’s stock, valued at approximately $4,308,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Trian Fund Management L.P. boosted its holdings in Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. Clifford Capital Partners LLC raised its position in Solventum by 22.6% in the third quarter. Clifford Capital Partners LLC now owns 279,479 shares of the company’s stock worth $19,485,000 after acquiring an additional 51,533 shares during the period. Kiltearn Partners LLP bought a new position in Solventum in the third quarter worth approximately $2,838,000. Bridgewater Associates LP bought a new position in Solventum in the third quarter worth approximately $1,316,000. Finally, Townsquare Capital LLC bought a new position in Solventum in the third quarter worth approximately $544,000.

Solventum Price Performance

Shares of SOLV stock opened at $72.48 on Thursday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company’s fifty day moving average price is $70.51 and its 200-day moving average price is $62.47. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Analyst Upgrades and Downgrades

SOLV has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating on the stock. Stifel Nicolaus initiated coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Wolfe Research initiated coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Wells Fargo & Company decreased their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Finally, Piper Sandler raised their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.